Drawback of Chimerism Analysis by XY-Fluorescence *In situ* Hybridization: Deception of a Relapse

Abstract

Chimerism is monitored by various methods in posttransplant patients. Interphase fluorescence *in situ* hybridization (FISH) for XY (sex) chromosomes is one of the methods commonly employed. It is a sensitive method in terms of the number of cells analyzed. Chimerism testing is done to detect graft rejection/failure which eventually may be a sign of relapse of the malignancy. The relapse of the disease initially happens in the marrow and then spreads to the peripheral blood. Hence, performing chimerism by XY-FISH in the peripheral blood may miss an early relapse. Here, we present one such case where there was 98% donor chimerism with the evidence of relapse in the bone marrow with all recipient metaphases in the bone marrow by conventional cytogenetics.

Keywords: Chimerism, posttransplant monitoring, XY-fluorescence *in situ* hybridization

Introduction

Chimerism is regularly monitored in posttransplant patients, and the presence of more than 95% chimerism indicates healthy graft function.^[1] The loss of chimerism on follow-up indicates graft failure which may be an early sign of disease relapse in the allogeneic stem cell transplantation (ASCT) for malignant disorders. Chimerism test can be performed in many ways. The most commonly applied method is the polymerase chain reaction (PCR) amplification of short tandem repeats (STR). In sex-mismatched transplants, interphase fluorescence *in situ* hybridization for X and Y chromosomes (XY-FISH) can be used to detect chimerism in transplants with opposite sex donors. We report a case of acute myeloid leukemia (AML) who had relapsed 2 years post-ASCT, in whom the chimerism analysis by XY-FISH was stable, but the conventional cytogenetics picked up the recipient cells in all mitoses.

Case Report

A 17-year-old girl presented to us with fever and on evaluation was diagnosed with AML intermediate risk. *FLT3*, *NPM1*, and *BCR-ABL1* were negative and conventional cytogenetics showed abnormality of short arm of chromosome 10 and long arm

of chromosome 17 [46, XX, add (10)(p15), del (17)(q21) [16]/ 46, XX [4]]. She received first induction 3 + 7 with daunorubicin (DNR) 60 mg/m² for 3 days as 1-h infusion and cytarabine 100 mg/m² per day for 7 days as continuous infusion. She was in morphological remission at the end of first induction. She then received the second induction 3 + 7 with DNR 45 mg/m² (institutional protocol) followed by one cycle of intermediate-dose cytarabine with 1.5 g/m² for 6 doses. Then, she underwent ASCT with her brother as the donor, who was 10/10 human leukocyte antigen match. The conditioning used was fludarabine-melphalan. Posttransplant, she developed acute graft-versus-host disease (GVHD) of the gut which was steroid responsive.

Chimerism analysis done by XY-FISH on the peripheral blood at day 30 was 100% donor. Day 100 chimerism by XY-FISH was also 100%. Cyclosporine was tapered and stopped at 4 months. Subsequently, chimerism was monitored once in 6 months by the peripheral blood XY-FISH, which was all 100%. After a disease-free survival of 2 years, she was diagnosed with a relapse of AML. At the time of relapse, chimerism was 98% utilizing XY-FISH [Figure 1], but conventional cytogenetics showed 47 XX, +7, t (10,17) del (6) in 20 metaphases [Figure 2].

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

**DVS Kiran Kumar,
Jayachandran
Perumal Kalaiyarasi**

Department of Medical
Oncology, Cancer
Institute (WIA), Chennai,
Tamil Nadu, India

Submitted: 13-Feb-2020

Revised: 11-Mar-2020

Accepted: 07-Apr-2020

Published: 29-Aug-2020

Address for correspondence:

Dr. Jayachandran Perumal
Kalaiyarasi,
Department of Medical
Oncology, Cancer
Institute (WIA), 38, Sardar
Patel Road, Guindy,
Chennai - 600 036, Tamil Nadu,
India.
E-mail: dr.pkjayachandran@
gmail.com

Access this article online

Website: www.ijmpo.org

DOI: 10.4103/ijmpo.ijmpo_60_20

Quick Response Code:

How to cite this article: Kiran Kumar DV, Perumal Kalaiyarasi J. Drawback of chimerism analysis by XY-fluorescence *in situ* hybridization: Deception of a relapse. Indian J Med Paediatr Oncol 2020;41:621-3.

Figure 1: XY-Fluorescence *in situ* hybridization analysis of the peripheral blood at relapse; Probe used: Metasystems fluorescence *in situ* hybridization probe (XA X/Y); Green: chromosome X; Red: chromosome Y – This figure shows four cells with one red and green signals in each, which signifies those cells is from a male (XY). One cell in the 3'O clock position shows 2 green signals, which signifies that it belongs to a female (XX)

She received salvage with fludarabine, high-dose cytarabine, filgrastim chemotherapy and had refractory disease at the end of salvage, and subsequently, she succumbed to her illness.

Discussion

Analysis of chimerism levels can be used to monitor the proportion of donor and recipient cells after allogeneic hematopoietic stem cell transplant (HSCT). It can identify graft rejection and can predict early relapse and GVHD.^[2] There are various methods by which chimerism can be estimated. These include XY-FISH, conventional karyotyping, restriction fragment length polymorphism (RFLP), red blood cell phenotyping, analysis of STR by PCR, single nucleotide polymorphism analysis, and Y chromosome PCR.^[3]

The sensitivity of XY-FISH for sex chromosomes is between 0.1% and 0.5% and conventional karyotyping is around 5%–10% for the detection of mixed chimerism.^[3] XY-FISH is done on interphase preparations with two differently labeled probes for X and Y chromosomes. It allows for rapid screening of many cells, and therefore, it is considered that high sensitivity can be achieved. Conventional cytogenetics depends on the culture of cells and analysis of mitoses and successful analysis depends on the presence of dividing cells and hence was considered to have low sensitivity. The relapse of leukemia initially starts in the bone marrow, and then, the leukemic cells spill over to the peripheral blood. Hence, in the context of detecting relapse, the sensitivity estimate of these methods is questionable. In the early stage of relapse, in the peripheral blood, the proportion of malignant cells is very low compared to the normal donor cells. Consequently, the analysis by XY-FISH would be done on majorly on donor cells which are in

Figure 2: Conventional cytogenetics of bone marrow – 47XX, +7, t (10,17) del (6) [20/20]

the G0 phase, and hence, there is a chance to miss early relapse. Moreover, the leukemic cells tend to have a high proliferative index, and hence, an interphase FISH would miss such cells during analysis. However, in conventional cytogenetics, the cells will be cultured, which leads to the replication of the rapidly dividing malignant recipient cells as compared to the quiescent donor cells and hence analyze recipient malignant cells majorly. This is reflected in our patient where chimerism by XY-FISH in the peripheral blood was 98% donor cells; however, the conventional karyotyping detected malignant recipient cells in all the mitoses.

Studies are done comparing XY-FISH to PCR analysis of Y chromosome-specific sequences and found that the XY-FISH missed a significant number of relapses compared to Y chromosome PCR.^[4] In conditions such as myelodysplastic syndrome and benign conditions such as pregnancy, XY-FISH is as good as conventional cytogenetics to detect chromosomal abnormalities.^[5] A study has been done for monitoring of chimerism posttransplant and was found that FISH is more sensitive.^[6] However, studies have not been done comparing the utility of these in the context of detecting relapse after ASCT.

We conclude that, in the context of detecting relapse after allogeneic HSCT, XY-FISH might not be an ideal modality for analyzing chimerism. Conventional karyotyping, given its ability to select rapidly dividing cells, might be better when compared to XY-FISH, but karyotyping lacks sensitivity. Hence, more sensitive methods such as RFLP, STR PCR, variable number tandem repeat, and Y chromosome PCR which are the current standard of care should be considered in the context of ASCT for malignant disorders over XY-FISH.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have

given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, *et al.* Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant? PLOS One 2016;11:e0154737.
2. Balon J, Hałaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A, *et al.* Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant 2005;35:1083-8.
3. Van Deerlin VM, Reshef R. Chimerism testing in allogeneic hematopoietic stem cell transplantation. In: Leonard DG, editor. Molecular Pathology in Clinical Practice. Cham: Springer International Publishing; 2016. p. 823-48.
4. Koldehoff M, Steckel NK, Hlinka M, Beelen DW, Elmaagacli AH. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol 2006;81:735-46.
5. He R, Wiktor AE, Durnick DK, Kurtin PJ, Van Dyke DL, Tefferi A, *et al.* Bone Marrow conventional karyotyping and fluorescence *in situ* hybridization: Defining an effective utilization strategy for evaluation of myelodysplastic syndromes. Am J Clin Pathol 2016;146:86-94.
6. Díez-Martín JL, Llamas P, Gosálvez J, López-Fernández C, Polo N, de la Fuente MS, *et al.* Conventional cytogenetics and FISH evaluation of chimerism after sex-mismatched bone marrow transplantation (BMT) and donor leukocyte infusion (DLI). Haematologica 1998;83:408-15.